Pathobiological role of MUC16 mucin(CA125) in ovarian cancer: Much more than a tumor biomarker
|
摘要
MUC16(CA125) has remained the mainstay for ovarian cancer assessment and management since the early 1980's. With the exception of HE4, it is the only reliable serum biomarker for ovarian cancer. MUC16 belongs to a family of high-molecular weight glycoproteins known as mucins. The mucin family is comprised of large secreted transmembrane proteins that includes MUC1, MUC4 and MUC16. These mucins are often overexpressed in a variety of malignancies. MUC1 and MUC4 have been shown to contribute to breast and pancreatic tumorigenesis. Recent studies have uncovered unique biological functions for MUC16 that go beyond its role as a biomarker for ovarian cancer. Here, we provide an overview of the literature to highlight the importance of MUC16 in ovarian cancer tumorigenesis. We focus on the growing literature describing the role of MUC16 in proliferation, migration, metastasis, tumorigenesis and drug resistance. Accumulating experimental evidence suggest that the C-terminal domain of MUC16 is critical to mediate theses effects. The importance of MUC16 in the pathogenesis of ovarian cancer emphasizes the need to fully understand the signaling capabilities of MUC16 C-terminal domain to develop more efficient strategies for the successful treatment of ovarian cancer.
MUC16(CA125) has remained the mainstay for ovarian cancer assessment and management since the early 1980's. With the exception of HE4, it is the only reliable serum biomarker for ovarian cancer. MUC16 belongs to a family of high-molecular weight glycoproteins known as mucins. The mucin family is comprised of large secreted transmembrane proteins that includes MUC1, MUC4 and MUC16. These mucins are often overexpressed in a variety of malignancies. MUC1 and MUC4 have been shown to contribute to breast and pancreatic tumorigenesis. Recent studies have uncovered unique biological functions for MUC16 that go beyond its role as a biomarker for ovarian cancer. Here, we provide an overview of the literature to highlight the importance of MUC16 in ovarian cancer tumorigenesis. We focus on the growing literature describing the role of MUC16 in proliferation, migration, metastasis, tumorigenesis and drug resistance. Accumulating experimental evidence suggest that the C-terminal domain of MUC16 is critical to mediate theses effects. The importance of MUC16 in the pathogenesis of ovarian cancer emphasizes the need to fully understand the signaling capabilities of MUC16 C-terminal domain to develop more efficient strategies for the successful treatment of ovarian cancer.
MUC16(CA125) has remained the mainstay for ovarian cancer assessment and management since the early 1980's. With the exception of HE4, it is the only reliable serum biomarker for ovarian cancer. MUC16 belongs to a family of high-molecular weight glycoproteins known as mucins. The mucin family is comprised of large secreted transmembrane proteins that includes MUC1, MUC4 and MUC16. These mucins are often overexpressed in a variety of malignancies. MUC1 and MUC4 have been shown to contribute to breast and pancreatic tumorigenesis. Recent studies have uncovered unique biological functions for MUC16 that go beyond its role as a biomarker for ovarian cancer. Here, we provide an overview of the literature to highlight the importance of MUC16 in ovarian cancer tumorigenesis. We focus on the growing literature describing the role of MUC16 in proliferation, migration, metastasis, tumorigenesis and drug resistance. Accumulating experimental evidence suggest that the C-terminal domain of MUC16 is critical to mediate theses effects. The importance of MUC16 in the pathogenesis of ovarian cancer emphasizes the need to fully understand the signaling capabilities of MUC16 C-terminal domain to develop more efficient strategies for the successful treatment of ovarian cancer.
引文
1 Badgwell D,Bast RC.Early detection of ovarian cancer.Dis Markers2007;23:397-410[PMID:18057523 DOI:10.1155/2007/309382]
2 Duffy MJ,Bonfrer JM,Kulpa J,Rustin GJ,Soletormos G,Torre GC,Tuxen MK,Zwirner M.CA125 in ovarian cancer:European Group on Tumor Markers guidelines for clinical use.Int J Gynecol Cancer 2005;15:679-691[PMID:16174214 DOI:10.1111/j.1525-1438.2005.00130.x]
3 Bast RC,Badgwell D,Lu Z,Marquez R,Rosen D,Liu J,Baggerly KA,Atkinson EN,Skates S,Zhang Z,Lokshin A,Menon U,Jacobs I,Lu K.New tumor markers:CA125 and beyond.Int J Gynecol Cancer 2005;15 Suppl 3:274-281[PMID:16343244 DOI:10 .1111/j.1525-1438.2005.00441.x]
4 Breitenecker G,Neunteufel W,Bieglmayer C,K?lbl H,Schieder K.Comparison between tissue and serum content of CA 125,CA 19-9,and carcinoembryonic antigen in ovarian tumors.Int J Gynecol Pathol 1989;8:97-102[PMID:2714933 DOI:10.1097/00004347-198906000-00002]
5 Davis HM,Zurawski VR,Bast RC,Klug TL.Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.Cancer Res 1986;46:6143-6148[PMID:2430690]
6 de la Cuesta R,Maestro ML,Solana J,Vidart JA,Escudero M,Iglesias E,Valor R.Tissue quantification of CA 125 in epithelial ovarian cancer.Int J Biol Markers 1999;14:106-114[PMID:10399630]
7 H?gdall EV,Christensen L,Kjaer SK,Blaakaer J,KjaerbyeThygesen A,Gayther S,Jacobs IJ,H?gdall CK.CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From The Danish“MALOVA”Ovarian Cancer Study.Gynecol Oncol 2007;104:508-515[PMID:17113137 DOI:10 .1016/j.ygyno.2006.09.028]
8 Kabawat SE,Bast RC,Bhan AK,Welch WR,Knapp RC,Colvin RB.Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.Int J Gynecol Pathol 1983;2:275-285[PMID:6196309 DOI:10.1097/00004347-198303000-00005]
9 Krivak TC,Tian C,Rose GS,Armstrong DK,Maxwell GL.A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy:an analysis of patients enrolled in GOG 172.Gynecol Oncol 2009;115:81-85[PMID:19596139 DOI:10.1016/j.ygyno.2009.06.021]
10 Miller RE,Rustin GJ.How to follow-up patients with epithelial ovarian cancer.Curr Opin Oncol 2010;22:498-502[PMID:20498597 DOI:10.1097/CCO.0b013e32833ae8b6]
11 Nap M.Immunohistochemistry of CA 125.Unusual expression in normal tissues,distribution in the human fetus and questions around its application in diagnostic pathology.Int J Biol Markers 1998;13:210-215[PMID:10228903]
12 Rustin GJ,Nelstrop AE,Tuxen MK,Lambert HE.Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study.Ann Oncol 1996;7:361-364[PMID:8805927 DOI:10.1093/oxfordjournals.annonc.a010602]
13 van Altena AM,Kolwijck E,Spanjer MJ,Hendriks JC,Massuger LF,de Hullu JA.CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer:a population-based study.Gynecol Oncol 2010;119:265-269[PMID:20797777 DOI:10.1016/j.ygyno.2010.07.025]
14 Vasudev NS,Trigonis I,Cairns DA,Hall GD,Jackson DP,Broadhead T,Buxton J,Hutson R,Nugent D,Perren TJ.The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.Arch Gynecol Obstet 2011;284:221-227[PMID:20803207 DOI:10.1007/s00404-010-1655-2]
15 Vergote IB,B?rmer OP,Abeler VM.Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.Am J Obstet Gynecol 1987;157:88-92[PMID:2440307 DOI:10.1016/S0002-9378(87)80352-6]
16 Zorn KK,Tian C,Mc Guire WP,Hoskins WJ,Markman M,Muggia FM,Rose PG,Ozols RF,Spriggs D,Armstrong DK.The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma:a Gynecologic Oncology Group study.Cancer2009;115:1028-1035[PMID:19156927 DOI:10.1002/cncr.24084]
17 Bast RC,Feeney M,Lazarus H,Nadler LM,Colvin RB,Knapp RC.Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest 1981;681:1331-1337[DOI:10.1172/JCI110380]
18 Bast RC,Klug TL,St John E,Jenison E,Niloff JM,Lazarus H,Berkowitz RS,Leavitt T,Griffiths CT,Parker L,Zurawski VR,Knapp RC.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med 1983;309:883-887[PMID:6310399 DOI:10.1056/NEJM198310133091503]
19 Yin BW,Lloyd KO.Molecular cloning of the CA125 ovarian cancer antigen:identification as a new mucin,MUC16.J Biol Chem2001;276:27371-27375[PMID:11369781 DOI:10.1074/jbc.M103554200]
20 Yin BW,Dnistrian A,Lloyd KO.Ovarian cancer antigen CA125is encoded by the MUC16 mucin gene.Int J Cancer 2002;98:737-740[PMID:11920644 DOI:10.1002/ijc.10250]
21 O’Brien TJ,Beard JB,Underwood LJ,Dennis RA,Santin AD,York L.The CA 125 gene:an extracellular superstructure dominated by repeat sequences.Tumour Biol 2001;22:348-366[PMID:11786729]
22 O’Brien TJ,Beard JB,Underwood LJ,Shigemasa K.The CA 125gene:a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure.Tumour Biol 2002;23:154-169[PMID:12218296 DOI:10 .1159/000064032]
23 Davies JR,Kirkham S,Svitacheva N,Thornton DJ,Carlstedt I.MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells.Int J Biochem Cell Biol 2007;39:1943-1954[PMID:17604678 DOI:10.1016/j.biocel.2007.05.013]
24 Gronowitz E,Pitk?nen S,Kjellmer I,Heikinheimo M,Strandvik B.Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis.Acta Paediatr 2003;92:1267-1271[PMID:14696845 DOI:10.1111/j.1651-2227.2003.tb00495.x]
25 Hattrup CL,Gendler SJ.Structure and function of the cell surface(tethered)mucins.Annu Rev Physiol 2008;70:431-457[PMID:17850209 DOI:10.1146/annurev.physiol.70.113006.100659]
26 Karlan BY,Amin W,Casper SE,Littlefield BA.Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells:inhibition by glucocorticoids.Cancer Res 1988;48:3502-3506[PMID:3285997]
27 Argüeso P,Spurr-Michaud S,Russo CL,Tisdale A,Gipson IK.MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.Invest Ophthalmol Vis Sci 2003;44:2487-2495[PMID:12766047 DOI:10.1167/iovs.02-0862]
28 Blalock TD,Spurr-Michaud SJ,Tisdale AS,Gipson IK.Release of membrane-associated mucins from ocular surface epithelia.Invest Ophthalmol Vis Sci 2008;49:1864-1871[PMID:18436821 DOI:10 .1167/iovs.07-1081]
29 Inatomi T,Spurr-Michaud S,Tisdale AS,Zhan Q,Feldman ST,Gipson IK.Expression of secretory mucin genes by human conjunctival epithelia.Invest Ophthalmol Vis Sci 1996;37:1684-1692[PMID:8675412]
30 J?ger K,Wu G,Sel S,Garreis F,Br?uer L,Paulsen FP.MUC16in the lacrimal apparatus.Histochem Cell Biol 2007;127:433-438[PMID:17211626 DOI:10.1007/s00418-006-0246-6]
31 Ataseven H,Oztürk ZA,Arhan M,Yüksel O,K?klüS,Ibi?M,Ba?ar O,Yilmaz FM,Yüksel I.Cancer antigen 125 levels in inflammatory bowel diseases.J Clin Lab Anal 2009;23:244-248[PMID:19623645 DOI:10.1002/jcla.20323]
32 Miralles C,Orea M,Espa?a P,Provencio M,Sánchez A,Cantos B,Cubedo R,Carcereny E,Bonilla F,Gea T.Cancer antigen 125associated with multiple benign and malignant pathologies.Ann Surg Oncol 2003;10:150-154[PMID:12620910 DOI:10.1245/ASO.2003.05.015]
33 Sikaris KA.CA125--a test with a change of heart.Heart Lung Circ 2011;20:634-640[PMID:20822954 DOI:10.1016/j.hlc.2010.08.001]
34 Xiaofang Y,Yue Z,Xialian X,Zhibin Y.Serum tumour markers in patients with chronic kidney disease.Scand J Clin Lab Invest 2007;67:661-667[PMID:17852811 DOI:10.1080/00365510701282326]
35 Dharma Rao T,Park KJ,Smith-Jones P,Iasonos A,Linkov I,Soslow RA,Spriggs DR.Novel monoclonal antibodies against the proximal(carboxy-terminal)portions of MUC16.Appl Immunohistochem Mol Morphol 2010;18:462-472[PMID:20453816 DOI:10.1097/PAI.0b013e3181dbfcd2]
36 Ali M,Lillehoj EP,Park Y,Kyo Y,Kim KC.Analysis of the proteome of human airway epithelial secretions.Proteome Sci 2011;9:4[PMID:21251289 DOI:10.1186/1477-5956-9-4]
37 Kesimer M,Ehre C,Burns KA,Davis CW,Sheehan JK,Pickles RJ.Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways.Mucosal Immunol 2013;6:379-392[PMID:22929560 DOI:10 .1038/mi.2012.81]
38 Moritani S,Ichihara S,Hasegawa M,Endo T,Oiwa M,Yoshikawa K,Sato Y,Aoyama H,Hayashi T,Kushima R.Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast.Are WT1,CA125,and GCDFP-15 useful in differential diagnosis?Hum Pathol 2008;39:666-671[PMID:18339419 DOI:10.1016/j.humpath.2007.09.009]
39 Haridas D,Chakraborty S,Ponnusamy MP,Lakshmanan I,Rachagani S,Cruz E,Kumar S,Das S,Lele SM,Anderson JM,Wittel UA,Hollingsworth MA,Batra SK.Pathobiological implications of MUC16 expression in pancreatic cancer.PLo S One 2011;6:e26839[PMID:22066010 DOI:10.1371/journal.pone.0026839]
40 Buys SS,Partridge E,Black A,Johnson CC,Lamerato L,Isaacs C,Reding DJ,Greenlee RT,Yokochi LA,Kessel B,Crawford ED,Church TR,Andriole GL,Weissfeld JL,Fouad MN,Chia D,O’Brien B,Ragard LR,Clapp JD,Rathmell JM,Riley TL,Hartge P,Pinsky PF,Zhu CS,Izmirlian G,Kramer BS,Miller AB,Xu JL,Prorok PC,Gohagan JK,Berg CD.Effect of screening on ovarian cancer mortality:the Prostate,Lung,Colorectal and Ovarian(PLCO)Cancer Screening Randomized Controlled Trial.JAMA 2011;305:2295-2303[PMID:21642681 DOI:10.1001/jama.2011.766]
41 Menon U,Gentry-Maharaj A,Hallett R,Ryan A,Burnell M,Sharma A,Lewis S,Davies S,Philpott S,Lopes A,Godfrey K,Oram D,Herod J,Williamson K,Seif MW,Scott I,Mould T,Woolas R,Murdoch J,Dobbs S,Amso NN,Leeson S,Cruickshank D,Mc Guire A,Campbell S,Fallowfield L,Singh N,Dawnay A,Skates SJ,Parmar M,Jacobs I.Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer,and stage distribution of detected cancers:results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening(UKCTOCS).Lancet Oncol 2009;10:327-340[PMID:19282241DOI:10.1016/S1470-2045(09)70026-9]
42 Jacobs I,Oram D,Fairbanks J,Turner J,Frost C,Grudzinskas JG.A risk of malignancy index incorporating CA 125,ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.Br J Obstet Gynaecol 1990;97:922-929[PMID:2223684DOI:10.1111/j.1471-0528.1990.tb02448.x]
43 Moore RG,Brown AK,Miller MC,Skates S,Allard WJ,Verch T,Steinhoff M,Messerlian G,Di Silvestro P,Granai CO,Bast RC.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol Oncol 2008;108:402-408[PMID:18061248 DOI:10.1016/j.ygyno.2007.10.017]
44 Moore RG,Mc Meekin DS,Brown AK,Di Silvestro P,Miller MC,Allard WJ,Gajewski W,Kurman R,Bast RC,Skates SJ.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol 2009;112:40-46[PMID:18851871 DOI:10.1016/j.ygyno.2008.08.031]
45 Moore RG,Miller MC,Disilvestro P,Landrum LM,Gajewski W,Ball JJ,Skates SJ.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.Obstet Gynecol 2011;118:280-288[PMID:21775843 DOI:10 .1097/AOG.0b013e318224fce2]
46 Bast RC,Skates S,Lokshin A,Moore RG.Differential diagnosis of a pelvic mass:improved algorithms and novel biomarkers.Int J Gynecol Cancer 2012;22 Suppl 1:S5-S8[PMID:22543921 DOI:10 .1097/IGC.0b013e318251c97d]
47 Lane D,Matte I,Garde-Granger P,Laplante C,Carignan A,Rancourt C,PichéA.Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.BMC Cancer 2015;15:492[PMID:26122176 DOI:10.1186/s12885-015-1511-7]
48 Moniaux N,Escande F,Porchet N,Aubert JP,Batra SK.Structural organization and classification of the human mucin genes.Front Biosci 2001;6:D1192-D1206[PMID:11578969]
49 Kui Wong N,Easton RL,Panico M,Sutton-Smith M,Morrison JC,Lattanzio FA,Morris HR,Clark GF,Dell A,Patankar MS.Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125.J Biol Chem 2003;278:28619-28634[PMID:12734200 DOI:10.1074/jbc.M302741200]
50 Duraisamy S,Ramasamy S,Kharbanda S,Kufe D.Distinct evolution of the human carcinoma-associated transmembrane mucins,MUC1,MUC4 AND MUC16.Gene 2006;373:28-34[PMID:16500040 DOI:10.1016/j.gene.2005.12.021]
51 Jonckheere N,Skrypek N,Frénois F,Van Seuningen I.Membranebound mucin modular domains:from structure to function.Biochimie 2013;95:1077-1086[PMID:23178705 DOI:10.1016/j.biochi.2012.11.005]
52 Das S,Rachagani S,Torres-Gonzalez MP,Lakshmanan I,Majhi PD,Smith LM,Wagner KU,Batra SK.Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.Oncotarget 2015;6:5772-5787[PMID:25691062 DOI:10.18632/oncotarget.3308]
53 Berek JS.Immunotherapy of ovarian cancer with antibodies:a focus on oregovomab.Expert Opin Biol Ther 2004;4:1159-1165[PMID:15268682 DOI:10.1517/14712598.4.7.1159]
54 Das S,Majhi PD,Al-Mugotir MH,Rachagani S,Sorgen P,Batra SK.Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.Sci Rep 2015;5:9759[PMID:26044153 DOI:10.1038/srep09759]
55 Govindarajan B,Menon BB,Spurr-Michaud S,Rastogi K,Gilmore MS,Argüeso P,Gipson IK.A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16from the epithelial glycocalyx barrier.PLo S One 2012;7:e32418[PMID:22412870 DOI:10.1371/journal.pone.0032418]
56 Fendrick JL,Konishi I,Geary SM,Parmley TH,Quirk JG,O’Brien TJ.CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line.Tumour Biol 1997;18:278-289[PMID:9276028 DOI:10.1159/000218041]
57 Konishi I,Fendrick JL,Parmley TH,Quirk JG,O’Brien TJ.Epidermal growth factor enhances secretion of the ovarian tumorassociated cancer antigen CA125 from the human amnion WISH cell line.J Soc Gynecol Investig 1994;1:89-96[PMID:9419754]
58 Berek JS,Taylor PT,Gordon A,Cunningham MJ,Finkler N,Orr J,Rivkin S,Schultes BC,Whiteside TL,Nicodemus CF.Randomized,placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.J Clin Oncol 2004;22:3507-3516[PMID:15337799 DOI:10.1200/JCO.2004.09.016]
59 Reinartz S,K?hler S,Schlebusch H,Krista K,Giffels P,Renke K,Huober J,M?bus V,Kreienberg R,Du Bois A,Sabbatini P,Wagner U.Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125:immunological response and survival(phase Ib/II).Clin Cancer Res 2004;10:1580-1587[PMID:15014007DOI:10.1158/1078-0432.CCR-03-0056]
60 Reinartz S,Hombach A,K?hler S,Schlebusch H,Wallwiener D,Abken H,Wagner U.Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+(MUC-16)ovarian cancer.Cancer Res2003;63:3234-3240[PMID:12810653]
61 Sabbatini P,Dupont J,Aghajanian C,Derosa F,Poynor E,Anderson S,Hensley M,Livingston P,Iasonos A,Spriggs D,Mc Guire W,Reinartz S,Schneider S,Grande C,Lele S,Rodabaugh K,Kepner J,Ferrone S,Odunsi K.Phase I study of abagovomab in patients with epithelial ovarian,fallopian tube,or primary peritoneal cancer.Clin Cancer Res 2006;12:5503-5510[PMID:17000686DOI:10.1158/1078-0432.CCR-05-2670]
62 Sabbatini P,Harter P,Scambia G,Sehouli J,Meier W,Wimberger P,Baumann KH,Kurzeder C,Schmalfeldt B,Cibula D,Bidzinski M,Casado A,Martoni A,Colombo N,Holloway RW,Selvaggi L,Li A,del Campo J,Cwiertka K,Pinter T,Vermorken JB,PujadeLauraine E,Scartoni S,Bertolotti M,Simonelli C,Capriati A,Maggi CA,Berek JS,Pfisterer J.Abagovomab as maintenance therapy in patients with epithelial ovarian cancer:a phase III trial of the AGO OVAR,COGI,GINECO,and GEICO--the MIMOSA study.J Clin Oncol 2013;31:1554-1561[PMID:23478059 DOI:10 .1200/JCO.2012.46.4057]
63 Li Y,Ren J,Yu W,Li Q,Kuwahara H,Yin L,Carraway KL,Kufe D.The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.J Biol Chem 2001;276:35239-35242[PMID:11483589 DOI:10 .1074/jbc.C100359200]
64 Schroeder JA,Thompson MC,Gardner MM,Gendler SJ.Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland.J Biol Chem 2001;276:13057-13064[PMID:11278868 DOI:10.1074/jbc.M011248200]
65 Pochampalli MR,el Bejjani RM,Schroeder JA.MUC1 is a novel regulator of Erb B1 receptor trafficking.Oncogene 2007;26:1693-1701[PMID:16983337 DOI:10.1038/sj.onc.1209976]
66 Ren J,Raina D,Chen W,Li G,Huang L,Kufe D.MUC1oncoprotein functions in activation of fibroblast growth factor receptor signaling.Mol Cancer Res 2006;4:873-883[PMID:17114345 DOI:10.1158/1541-7786.MCR-06-0204]
67 Bafna S,Kaur S,Batra SK.Membrane-bound mucins:the mechanistic basis for alterations in the growth and survival of cancer cells.Oncogene 2010;29:2893-2904[PMID:20348949DOI:10.1038/onc.2010.87]
68 Comamala M,Pinard M,Thériault C,Matte I,Albert A,Boivin M,Beaudin J,PichéA,Rancourt C.Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.Br J Cancer 2011;104:989-999[PMID:21326240 DOI:10 .1038/bjc.2011.34]
69 Lakshmanan I,Ponnusamy MP,Das S,Chakraborty S,Haridas D,Mukhopadhyay P,Lele SM,Batra SK.MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.Oncogene 2012;31:805-817[PMID:21785467 DOI:10.1038/onc.2011.297]
70 Yamamoto M,Bharti A,Li Y,Kufe D.Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion.J Biol Chem 1997;272:12492-12494[PMID:9139698DOI:10.1074/jbc.272.19.12492]
71 Wen Y,Caffrey TC,Wheelock MJ,Johnson KR,Hollingsworth MA.Nuclear association of the cytoplasmic tail of MUC1 and betacatenin.J Biol Chem 2003;278:38029-38039[PMID:12832415DOI:10.1074/jbc.M304333200]
72 Huang L,Chen D,Liu D,Yin L,Kharbanda S,Kufe D.MUC1oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.Cancer Res 2005;65:10413-10422[PMID:16288032 DOI:10.1158/0008-5472.CAN-05-2474]
73 Cancer Genome Atlas Research Network.Integrated genomic analyses of ovarian carcinoma.Nature 2011;474:609-615[PMID:21720365 DOI:10.1038/nature10166]
74 Haridas D,Ponnusamy MP,Chugh S,Lakshmanan I,Seshacharyulu P,Batra SK.MUC16:molecular analysis and its functional implications in benign and malignant conditions.FASEB J 2014;28:4183-4199[PMID:25002120 DOI:10.1096/fj.14-257352]
75 Kohlgraf KG,Gawron AJ,Higashi M,Meza JL,Burdick MD,Kitajima S,Kelly DL,Caffrey TC,Hollingsworth MA.Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line.Cancer Res2003;63:5011-5020[PMID:12941828]
76 Singh AP,Moniaux N,Chauhan SC,Meza JL,Batra SK.Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis.Cancer Res 2004;64:622-630[PMID:14744777 DOI:10 .1158/0008-5472.CAN-03-2636]
77 Chaturvedi P,Singh AP,Moniaux N,Senapati S,Chakraborty S,Meza JL,Batra SK.MUC4 mucin potentiates pancreatic tumor cell proliferation,survival,and invasive properties and interferes with its interaction to extracellular matrix proteins.Mol Cancer Res 2007;5:309-320[PMID:17406026 DOI:10.1158/1541-7786.MCR-06-0353]
78 Thériault C,Pinard M,Comamala M,Migneault M,Beaudin J,Matte I,Boivin M,PichéA,Rancourt C.MUC16(CA125)regulates epithelial ovarian cancer cell growth,tumorigenesis and metastasis.Gynecol Oncol 2011;121:434-443[PMID:21421261DOI:10.1016/j.ygyno.2011.02.020]
79 Reinartz S,Failer S,Schuell T,Wagner U.CA125(MUC16)gene silencing suppresses growth properties of ovarian and breast cancer cells.Eur J Cancer 2012;48:1558-1569[PMID:21852110 DOI:10 .1016/j.ejca.2011.07.004]
80 Shukla SK,Gunda V,Abrego J,Haridas D,Mishra A,Souchek J,Chaika NV,Yu F,Sasson AR,Lazenby AJ,Batra SK,Singh PK.MUC16-mediated activation of m TOR and c-Myc reprograms pancreatic cancer metabolism.Oncotarget 2015;6:19118-19131[PMID:26046375 DOI:10.18632/oncotarget.4078]
81 Giannakouros P,Comamala M,Matte I,Rancourt C,PichéA.MUC16 mucin(CA125)regulates the formation of multicellular aggregates by alteringβ-catenin signaling.Am J Cancer Res 2015;5:219-230[PMID:25628932]
82 Giannakouros P,Matte I,Rancourt C,PichéA.Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin(CA125)is driven by its cytoplasmic tail.Int J Oncol 2015;46:91-98[PMID:25338620 DOI:10.3892/ijo.2014.2707]
83 Grille SJ,Bellacosa A,Upson J,Klein-Szanto AJ,van Roy F,LeeKwon W,Donowitz M,Tsichlis PN,Larue L.The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines.Cancer Res 2003;63:2172-2178[PMID:12727836]
84 Balmanno K,Cook SJ.Tumour cell survival signalling by the ERK1/2 pathway.Cell Death Differ 2009;16:368-377[PMID:18846109 DOI:10.1038/cdd.2008.148]
85 Rao TD,Tian H,Ma X,Yan X,Thapi S,Schultz N,Rosales N,Monette S,Wang A,Hyman DM,Levine DA,Solit D,Spriggs DR.Expression of the Carboxy-Terminal Portion of MUC16/CA125Induces Transformation and Tumor Invasion.PLo S One 2015;10:e0126633[PMID:25965947 DOI:10.1371/journal.pone.0126633]
86 Al-Alem L,Curry TE.Ovarian cancer:involvement of the matrix metalloproteinases.Reproduction 2015;150:R55-R64[PMID:25918438 DOI:10.1530/REP-14-0546]
87 Kulbe H,Chakravarty P,Leinster DA,Charles KA,Kwong J,Thompson RG,Coward JI,Schioppa T,Robinson SC,Gallagher WM,Galletta L,Salako MA,Smyth JF,Hagemann T,Brennan DJ,Bowtell DD,Balkwill FR.A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.Cancer Res 2012;72:66-75[PMID:22065722 DOI:10.1158/0008-5472.CAN-11-2178]
88 Carraway KL,Funes M,Workman HC,Sweeney C.Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways.Curr Top Dev Biol 2007;78:1-22[PMID:17338913 DOI:10.1016/S0070-2153(06)78001-2]
89 Ren J,Agata N,Chen D,Li Y,Yu WH,Huang L,Raina D,Chen W,Kharbanda S,Kufe D.Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.Cancer Cell 2004;5:163-175[PMID:14998492]
90 Singh PK,Hollingsworth MA.Cell surface-associated mucins in signal transduction.Trends Cell Biol 2006;16:467-476[PMID:16904320 DOI:10.1016/j.tcb.2006.07.006]
91 Li Y,Liu D,Chen D,Kharbanda S,Kufe D.Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.Oncogene 2003;22:6107-6110[PMID:12955090 DOI:10.1038/sj.onc.1206732]
92 Bafna S,Singh AP,Moniaux N,Eudy JD,Meza JL,Batra SK.MUC4,a multifunctional transmembrane glycoprotein,induces oncogenic transformation of NIH3T3 mouse fibroblast cells.Cancer Res 2008;68:9231-9238[PMID:19010895 DOI:10 .1158/0008-5472.CAN-08-3135]
93 Auersperg N,Wong AS,Choi KC,Kang SK,Leung PC.Ovarian surface epithelium:biology,endocrinology,and pathology.Endocr Rev 2001;22:255-288[PMID:11294827 DOI:10.1210/er.22.2.255]
94 Boivin M,Lane D,PichéA,Rancourt C.CA125(MUC16)tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.Gynecol Oncol 2009;115:407-413[PMID:19747716 DOI:10.1016/j.ygyno.2009.08.007]
95 Yin L,Huang L,Kufe D.MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress.J Biol Chem 2004;279:45721-45727[PMID:15322085 DOI:10.1074/jbc.M408027200]
96 Nemoto S,Finkel T.Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway.Science 2002;295:2450-2452[PMID:11884717 DOI:10.1126/science.1069004]
97 Tran H,Brunet A,Grenier JM,Datta SR,Fornace AJ,Di Stefano PS,Chiang LW,Greenberg ME.DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45protein.Science 2002;296:530-534[PMID:11964479 DOI:10 .1126/science.1068712]
98 Khaider NG,Lane D,Matte I,Rancourt C,PichéA.Targeted ovarian cancer treatment:the TRAILs of resistance.Am J Cancer Res 2012;2:75-92[PMID:22206047]
99 Ashkenazi A,Dixit VM.Death receptors:signaling and modulation.Science 1998;281:1305-1308[PMID:9721089 DOI:10.1126/science.281.5381.1305]
100 Ashkenazi A,Holland P,Eckhardt SG.Ligand-based targeting of apoptosis in cancer:the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand(rh Apo2L/TRAIL).J Clin Oncol 2008;26:3621-3630[PMID:18640940 DOI:10.1200/JCO.2007.15.7198]
101 Walczak H,Miller RE,Ariail K,Gliniak B,Griffith TS,Kubin M,Chin W,Jones J,Woodward A,Le T,Smith C,Smolak P,Goodwin RG,Rauch CT,Schuh JC,Lynch DH.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.Nat Med1999;5:157-163[PMID:9930862 DOI:10.1038/5517]
102 Lane D,Cartier A,L’Espérance S,C?téM,Rancourt C,PichéA.Differential induction of apoptosis by tumor necrosis factorrelated apoptosis-inducing ligand in human ovarian carcinoma cells.Gynecol Oncol 2004;93:594-604[PMID:15196850 DOI:10 .1016/j.ygyno.2004.03.029]
103 Kischkel FC,Lawrence DA,Chuntharapai A,Schow P,Kim KJ,Ashkenazi A.Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.Immunity 2000;12:611-620[PMID:10894161 DOI:10.1016/S1074-7613(00)80212-5]
104 Kischkel FC,Hellbardt S,Behrmann I,Germer M,Pawlita M,Krammer PH,Peter ME.Cytotoxicity-dependent APO-1(Fas/CD95)-associated proteins form a death-inducing signaling complex(DISC)with the receptor.EMBO J 1995;14:5579-5588[PMID:8521815]
105 Krueger A,Baumann S,Krammer PH,Kirchhoff S.FLICEinhibitory proteins:regulators of death receptor-mediated apoptosis.Mol Cell Biol 2001;21:8247-8254[PMID:11713262 DOI:10 .1128/MCB.21.24.8247-8254.2001]
106 Matte I,Lane D,Boivin M,Rancourt C,PichéA.MUC16 mucin(CA125)attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.BMC Cancer 2014;14:234[PMID:24690311 DOI:10.1186/1471-2407-14-234]
107 Agata N,Ahmad R,Kawano T,Raina D,Kharbanda S,Kufe D.MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8.Cancer Res 2008;68:6136-6144[PMID:18676836 DOI:10.1158/0008-5472.CAN-08-0464]
2 Duffy MJ,Bonfrer JM,Kulpa J,Rustin GJ,Soletormos G,Torre GC,Tuxen MK,Zwirner M.CA125 in ovarian cancer:European Group on Tumor Markers guidelines for clinical use.Int J Gynecol Cancer 2005;15:679-691[PMID:16174214 DOI:10.1111/j.1525-1438.2005.00130.x]
3 Bast RC,Badgwell D,Lu Z,Marquez R,Rosen D,Liu J,Baggerly KA,Atkinson EN,Skates S,Zhang Z,Lokshin A,Menon U,Jacobs I,Lu K.New tumor markers:CA125 and beyond.Int J Gynecol Cancer 2005;15 Suppl 3:274-281[PMID:16343244 DOI:10 .1111/j.1525-1438.2005.00441.x]
4 Breitenecker G,Neunteufel W,Bieglmayer C,K?lbl H,Schieder K.Comparison between tissue and serum content of CA 125,CA 19-9,and carcinoembryonic antigen in ovarian tumors.Int J Gynecol Pathol 1989;8:97-102[PMID:2714933 DOI:10.1097/00004347-198906000-00002]
5 Davis HM,Zurawski VR,Bast RC,Klug TL.Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.Cancer Res 1986;46:6143-6148[PMID:2430690]
6 de la Cuesta R,Maestro ML,Solana J,Vidart JA,Escudero M,Iglesias E,Valor R.Tissue quantification of CA 125 in epithelial ovarian cancer.Int J Biol Markers 1999;14:106-114[PMID:10399630]
7 H?gdall EV,Christensen L,Kjaer SK,Blaakaer J,KjaerbyeThygesen A,Gayther S,Jacobs IJ,H?gdall CK.CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From The Danish“MALOVA”Ovarian Cancer Study.Gynecol Oncol 2007;104:508-515[PMID:17113137 DOI:10 .1016/j.ygyno.2006.09.028]
8 Kabawat SE,Bast RC,Bhan AK,Welch WR,Knapp RC,Colvin RB.Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.Int J Gynecol Pathol 1983;2:275-285[PMID:6196309 DOI:10.1097/00004347-198303000-00005]
9 Krivak TC,Tian C,Rose GS,Armstrong DK,Maxwell GL.A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy:an analysis of patients enrolled in GOG 172.Gynecol Oncol 2009;115:81-85[PMID:19596139 DOI:10.1016/j.ygyno.2009.06.021]
10 Miller RE,Rustin GJ.How to follow-up patients with epithelial ovarian cancer.Curr Opin Oncol 2010;22:498-502[PMID:20498597 DOI:10.1097/CCO.0b013e32833ae8b6]
11 Nap M.Immunohistochemistry of CA 125.Unusual expression in normal tissues,distribution in the human fetus and questions around its application in diagnostic pathology.Int J Biol Markers 1998;13:210-215[PMID:10228903]
12 Rustin GJ,Nelstrop AE,Tuxen MK,Lambert HE.Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study.Ann Oncol 1996;7:361-364[PMID:8805927 DOI:10.1093/oxfordjournals.annonc.a010602]
13 van Altena AM,Kolwijck E,Spanjer MJ,Hendriks JC,Massuger LF,de Hullu JA.CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer:a population-based study.Gynecol Oncol 2010;119:265-269[PMID:20797777 DOI:10.1016/j.ygyno.2010.07.025]
14 Vasudev NS,Trigonis I,Cairns DA,Hall GD,Jackson DP,Broadhead T,Buxton J,Hutson R,Nugent D,Perren TJ.The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.Arch Gynecol Obstet 2011;284:221-227[PMID:20803207 DOI:10.1007/s00404-010-1655-2]
15 Vergote IB,B?rmer OP,Abeler VM.Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.Am J Obstet Gynecol 1987;157:88-92[PMID:2440307 DOI:10.1016/S0002-9378(87)80352-6]
16 Zorn KK,Tian C,Mc Guire WP,Hoskins WJ,Markman M,Muggia FM,Rose PG,Ozols RF,Spriggs D,Armstrong DK.The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma:a Gynecologic Oncology Group study.Cancer2009;115:1028-1035[PMID:19156927 DOI:10.1002/cncr.24084]
17 Bast RC,Feeney M,Lazarus H,Nadler LM,Colvin RB,Knapp RC.Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest 1981;681:1331-1337[DOI:10.1172/JCI110380]
18 Bast RC,Klug TL,St John E,Jenison E,Niloff JM,Lazarus H,Berkowitz RS,Leavitt T,Griffiths CT,Parker L,Zurawski VR,Knapp RC.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med 1983;309:883-887[PMID:6310399 DOI:10.1056/NEJM198310133091503]
19 Yin BW,Lloyd KO.Molecular cloning of the CA125 ovarian cancer antigen:identification as a new mucin,MUC16.J Biol Chem2001;276:27371-27375[PMID:11369781 DOI:10.1074/jbc.M103554200]
20 Yin BW,Dnistrian A,Lloyd KO.Ovarian cancer antigen CA125is encoded by the MUC16 mucin gene.Int J Cancer 2002;98:737-740[PMID:11920644 DOI:10.1002/ijc.10250]
21 O’Brien TJ,Beard JB,Underwood LJ,Dennis RA,Santin AD,York L.The CA 125 gene:an extracellular superstructure dominated by repeat sequences.Tumour Biol 2001;22:348-366[PMID:11786729]
22 O’Brien TJ,Beard JB,Underwood LJ,Shigemasa K.The CA 125gene:a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure.Tumour Biol 2002;23:154-169[PMID:12218296 DOI:10 .1159/000064032]
23 Davies JR,Kirkham S,Svitacheva N,Thornton DJ,Carlstedt I.MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells.Int J Biochem Cell Biol 2007;39:1943-1954[PMID:17604678 DOI:10.1016/j.biocel.2007.05.013]
24 Gronowitz E,Pitk?nen S,Kjellmer I,Heikinheimo M,Strandvik B.Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis.Acta Paediatr 2003;92:1267-1271[PMID:14696845 DOI:10.1111/j.1651-2227.2003.tb00495.x]
25 Hattrup CL,Gendler SJ.Structure and function of the cell surface(tethered)mucins.Annu Rev Physiol 2008;70:431-457[PMID:17850209 DOI:10.1146/annurev.physiol.70.113006.100659]
26 Karlan BY,Amin W,Casper SE,Littlefield BA.Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells:inhibition by glucocorticoids.Cancer Res 1988;48:3502-3506[PMID:3285997]
27 Argüeso P,Spurr-Michaud S,Russo CL,Tisdale A,Gipson IK.MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.Invest Ophthalmol Vis Sci 2003;44:2487-2495[PMID:12766047 DOI:10.1167/iovs.02-0862]
28 Blalock TD,Spurr-Michaud SJ,Tisdale AS,Gipson IK.Release of membrane-associated mucins from ocular surface epithelia.Invest Ophthalmol Vis Sci 2008;49:1864-1871[PMID:18436821 DOI:10 .1167/iovs.07-1081]
29 Inatomi T,Spurr-Michaud S,Tisdale AS,Zhan Q,Feldman ST,Gipson IK.Expression of secretory mucin genes by human conjunctival epithelia.Invest Ophthalmol Vis Sci 1996;37:1684-1692[PMID:8675412]
30 J?ger K,Wu G,Sel S,Garreis F,Br?uer L,Paulsen FP.MUC16in the lacrimal apparatus.Histochem Cell Biol 2007;127:433-438[PMID:17211626 DOI:10.1007/s00418-006-0246-6]
31 Ataseven H,Oztürk ZA,Arhan M,Yüksel O,K?klüS,Ibi?M,Ba?ar O,Yilmaz FM,Yüksel I.Cancer antigen 125 levels in inflammatory bowel diseases.J Clin Lab Anal 2009;23:244-248[PMID:19623645 DOI:10.1002/jcla.20323]
32 Miralles C,Orea M,Espa?a P,Provencio M,Sánchez A,Cantos B,Cubedo R,Carcereny E,Bonilla F,Gea T.Cancer antigen 125associated with multiple benign and malignant pathologies.Ann Surg Oncol 2003;10:150-154[PMID:12620910 DOI:10.1245/ASO.2003.05.015]
33 Sikaris KA.CA125--a test with a change of heart.Heart Lung Circ 2011;20:634-640[PMID:20822954 DOI:10.1016/j.hlc.2010.08.001]
34 Xiaofang Y,Yue Z,Xialian X,Zhibin Y.Serum tumour markers in patients with chronic kidney disease.Scand J Clin Lab Invest 2007;67:661-667[PMID:17852811 DOI:10.1080/00365510701282326]
35 Dharma Rao T,Park KJ,Smith-Jones P,Iasonos A,Linkov I,Soslow RA,Spriggs DR.Novel monoclonal antibodies against the proximal(carboxy-terminal)portions of MUC16.Appl Immunohistochem Mol Morphol 2010;18:462-472[PMID:20453816 DOI:10.1097/PAI.0b013e3181dbfcd2]
36 Ali M,Lillehoj EP,Park Y,Kyo Y,Kim KC.Analysis of the proteome of human airway epithelial secretions.Proteome Sci 2011;9:4[PMID:21251289 DOI:10.1186/1477-5956-9-4]
37 Kesimer M,Ehre C,Burns KA,Davis CW,Sheehan JK,Pickles RJ.Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways.Mucosal Immunol 2013;6:379-392[PMID:22929560 DOI:10 .1038/mi.2012.81]
38 Moritani S,Ichihara S,Hasegawa M,Endo T,Oiwa M,Yoshikawa K,Sato Y,Aoyama H,Hayashi T,Kushima R.Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast.Are WT1,CA125,and GCDFP-15 useful in differential diagnosis?Hum Pathol 2008;39:666-671[PMID:18339419 DOI:10.1016/j.humpath.2007.09.009]
39 Haridas D,Chakraborty S,Ponnusamy MP,Lakshmanan I,Rachagani S,Cruz E,Kumar S,Das S,Lele SM,Anderson JM,Wittel UA,Hollingsworth MA,Batra SK.Pathobiological implications of MUC16 expression in pancreatic cancer.PLo S One 2011;6:e26839[PMID:22066010 DOI:10.1371/journal.pone.0026839]
40 Buys SS,Partridge E,Black A,Johnson CC,Lamerato L,Isaacs C,Reding DJ,Greenlee RT,Yokochi LA,Kessel B,Crawford ED,Church TR,Andriole GL,Weissfeld JL,Fouad MN,Chia D,O’Brien B,Ragard LR,Clapp JD,Rathmell JM,Riley TL,Hartge P,Pinsky PF,Zhu CS,Izmirlian G,Kramer BS,Miller AB,Xu JL,Prorok PC,Gohagan JK,Berg CD.Effect of screening on ovarian cancer mortality:the Prostate,Lung,Colorectal and Ovarian(PLCO)Cancer Screening Randomized Controlled Trial.JAMA 2011;305:2295-2303[PMID:21642681 DOI:10.1001/jama.2011.766]
41 Menon U,Gentry-Maharaj A,Hallett R,Ryan A,Burnell M,Sharma A,Lewis S,Davies S,Philpott S,Lopes A,Godfrey K,Oram D,Herod J,Williamson K,Seif MW,Scott I,Mould T,Woolas R,Murdoch J,Dobbs S,Amso NN,Leeson S,Cruickshank D,Mc Guire A,Campbell S,Fallowfield L,Singh N,Dawnay A,Skates SJ,Parmar M,Jacobs I.Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer,and stage distribution of detected cancers:results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening(UKCTOCS).Lancet Oncol 2009;10:327-340[PMID:19282241DOI:10.1016/S1470-2045(09)70026-9]
42 Jacobs I,Oram D,Fairbanks J,Turner J,Frost C,Grudzinskas JG.A risk of malignancy index incorporating CA 125,ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.Br J Obstet Gynaecol 1990;97:922-929[PMID:2223684DOI:10.1111/j.1471-0528.1990.tb02448.x]
43 Moore RG,Brown AK,Miller MC,Skates S,Allard WJ,Verch T,Steinhoff M,Messerlian G,Di Silvestro P,Granai CO,Bast RC.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol Oncol 2008;108:402-408[PMID:18061248 DOI:10.1016/j.ygyno.2007.10.017]
44 Moore RG,Mc Meekin DS,Brown AK,Di Silvestro P,Miller MC,Allard WJ,Gajewski W,Kurman R,Bast RC,Skates SJ.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol 2009;112:40-46[PMID:18851871 DOI:10.1016/j.ygyno.2008.08.031]
45 Moore RG,Miller MC,Disilvestro P,Landrum LM,Gajewski W,Ball JJ,Skates SJ.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.Obstet Gynecol 2011;118:280-288[PMID:21775843 DOI:10 .1097/AOG.0b013e318224fce2]
46 Bast RC,Skates S,Lokshin A,Moore RG.Differential diagnosis of a pelvic mass:improved algorithms and novel biomarkers.Int J Gynecol Cancer 2012;22 Suppl 1:S5-S8[PMID:22543921 DOI:10 .1097/IGC.0b013e318251c97d]
47 Lane D,Matte I,Garde-Granger P,Laplante C,Carignan A,Rancourt C,PichéA.Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.BMC Cancer 2015;15:492[PMID:26122176 DOI:10.1186/s12885-015-1511-7]
48 Moniaux N,Escande F,Porchet N,Aubert JP,Batra SK.Structural organization and classification of the human mucin genes.Front Biosci 2001;6:D1192-D1206[PMID:11578969]
49 Kui Wong N,Easton RL,Panico M,Sutton-Smith M,Morrison JC,Lattanzio FA,Morris HR,Clark GF,Dell A,Patankar MS.Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125.J Biol Chem 2003;278:28619-28634[PMID:12734200 DOI:10.1074/jbc.M302741200]
50 Duraisamy S,Ramasamy S,Kharbanda S,Kufe D.Distinct evolution of the human carcinoma-associated transmembrane mucins,MUC1,MUC4 AND MUC16.Gene 2006;373:28-34[PMID:16500040 DOI:10.1016/j.gene.2005.12.021]
51 Jonckheere N,Skrypek N,Frénois F,Van Seuningen I.Membranebound mucin modular domains:from structure to function.Biochimie 2013;95:1077-1086[PMID:23178705 DOI:10.1016/j.biochi.2012.11.005]
52 Das S,Rachagani S,Torres-Gonzalez MP,Lakshmanan I,Majhi PD,Smith LM,Wagner KU,Batra SK.Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.Oncotarget 2015;6:5772-5787[PMID:25691062 DOI:10.18632/oncotarget.3308]
53 Berek JS.Immunotherapy of ovarian cancer with antibodies:a focus on oregovomab.Expert Opin Biol Ther 2004;4:1159-1165[PMID:15268682 DOI:10.1517/14712598.4.7.1159]
54 Das S,Majhi PD,Al-Mugotir MH,Rachagani S,Sorgen P,Batra SK.Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.Sci Rep 2015;5:9759[PMID:26044153 DOI:10.1038/srep09759]
55 Govindarajan B,Menon BB,Spurr-Michaud S,Rastogi K,Gilmore MS,Argüeso P,Gipson IK.A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16from the epithelial glycocalyx barrier.PLo S One 2012;7:e32418[PMID:22412870 DOI:10.1371/journal.pone.0032418]
56 Fendrick JL,Konishi I,Geary SM,Parmley TH,Quirk JG,O’Brien TJ.CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line.Tumour Biol 1997;18:278-289[PMID:9276028 DOI:10.1159/000218041]
57 Konishi I,Fendrick JL,Parmley TH,Quirk JG,O’Brien TJ.Epidermal growth factor enhances secretion of the ovarian tumorassociated cancer antigen CA125 from the human amnion WISH cell line.J Soc Gynecol Investig 1994;1:89-96[PMID:9419754]
58 Berek JS,Taylor PT,Gordon A,Cunningham MJ,Finkler N,Orr J,Rivkin S,Schultes BC,Whiteside TL,Nicodemus CF.Randomized,placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.J Clin Oncol 2004;22:3507-3516[PMID:15337799 DOI:10.1200/JCO.2004.09.016]
59 Reinartz S,K?hler S,Schlebusch H,Krista K,Giffels P,Renke K,Huober J,M?bus V,Kreienberg R,Du Bois A,Sabbatini P,Wagner U.Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125:immunological response and survival(phase Ib/II).Clin Cancer Res 2004;10:1580-1587[PMID:15014007DOI:10.1158/1078-0432.CCR-03-0056]
60 Reinartz S,Hombach A,K?hler S,Schlebusch H,Wallwiener D,Abken H,Wagner U.Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+(MUC-16)ovarian cancer.Cancer Res2003;63:3234-3240[PMID:12810653]
61 Sabbatini P,Dupont J,Aghajanian C,Derosa F,Poynor E,Anderson S,Hensley M,Livingston P,Iasonos A,Spriggs D,Mc Guire W,Reinartz S,Schneider S,Grande C,Lele S,Rodabaugh K,Kepner J,Ferrone S,Odunsi K.Phase I study of abagovomab in patients with epithelial ovarian,fallopian tube,or primary peritoneal cancer.Clin Cancer Res 2006;12:5503-5510[PMID:17000686DOI:10.1158/1078-0432.CCR-05-2670]
62 Sabbatini P,Harter P,Scambia G,Sehouli J,Meier W,Wimberger P,Baumann KH,Kurzeder C,Schmalfeldt B,Cibula D,Bidzinski M,Casado A,Martoni A,Colombo N,Holloway RW,Selvaggi L,Li A,del Campo J,Cwiertka K,Pinter T,Vermorken JB,PujadeLauraine E,Scartoni S,Bertolotti M,Simonelli C,Capriati A,Maggi CA,Berek JS,Pfisterer J.Abagovomab as maintenance therapy in patients with epithelial ovarian cancer:a phase III trial of the AGO OVAR,COGI,GINECO,and GEICO--the MIMOSA study.J Clin Oncol 2013;31:1554-1561[PMID:23478059 DOI:10 .1200/JCO.2012.46.4057]
63 Li Y,Ren J,Yu W,Li Q,Kuwahara H,Yin L,Carraway KL,Kufe D.The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.J Biol Chem 2001;276:35239-35242[PMID:11483589 DOI:10 .1074/jbc.C100359200]
64 Schroeder JA,Thompson MC,Gardner MM,Gendler SJ.Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland.J Biol Chem 2001;276:13057-13064[PMID:11278868 DOI:10.1074/jbc.M011248200]
65 Pochampalli MR,el Bejjani RM,Schroeder JA.MUC1 is a novel regulator of Erb B1 receptor trafficking.Oncogene 2007;26:1693-1701[PMID:16983337 DOI:10.1038/sj.onc.1209976]
66 Ren J,Raina D,Chen W,Li G,Huang L,Kufe D.MUC1oncoprotein functions in activation of fibroblast growth factor receptor signaling.Mol Cancer Res 2006;4:873-883[PMID:17114345 DOI:10.1158/1541-7786.MCR-06-0204]
67 Bafna S,Kaur S,Batra SK.Membrane-bound mucins:the mechanistic basis for alterations in the growth and survival of cancer cells.Oncogene 2010;29:2893-2904[PMID:20348949DOI:10.1038/onc.2010.87]
68 Comamala M,Pinard M,Thériault C,Matte I,Albert A,Boivin M,Beaudin J,PichéA,Rancourt C.Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.Br J Cancer 2011;104:989-999[PMID:21326240 DOI:10 .1038/bjc.2011.34]
69 Lakshmanan I,Ponnusamy MP,Das S,Chakraborty S,Haridas D,Mukhopadhyay P,Lele SM,Batra SK.MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.Oncogene 2012;31:805-817[PMID:21785467 DOI:10.1038/onc.2011.297]
70 Yamamoto M,Bharti A,Li Y,Kufe D.Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion.J Biol Chem 1997;272:12492-12494[PMID:9139698DOI:10.1074/jbc.272.19.12492]
71 Wen Y,Caffrey TC,Wheelock MJ,Johnson KR,Hollingsworth MA.Nuclear association of the cytoplasmic tail of MUC1 and betacatenin.J Biol Chem 2003;278:38029-38039[PMID:12832415DOI:10.1074/jbc.M304333200]
72 Huang L,Chen D,Liu D,Yin L,Kharbanda S,Kufe D.MUC1oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.Cancer Res 2005;65:10413-10422[PMID:16288032 DOI:10.1158/0008-5472.CAN-05-2474]
73 Cancer Genome Atlas Research Network.Integrated genomic analyses of ovarian carcinoma.Nature 2011;474:609-615[PMID:21720365 DOI:10.1038/nature10166]
74 Haridas D,Ponnusamy MP,Chugh S,Lakshmanan I,Seshacharyulu P,Batra SK.MUC16:molecular analysis and its functional implications in benign and malignant conditions.FASEB J 2014;28:4183-4199[PMID:25002120 DOI:10.1096/fj.14-257352]
75 Kohlgraf KG,Gawron AJ,Higashi M,Meza JL,Burdick MD,Kitajima S,Kelly DL,Caffrey TC,Hollingsworth MA.Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line.Cancer Res2003;63:5011-5020[PMID:12941828]
76 Singh AP,Moniaux N,Chauhan SC,Meza JL,Batra SK.Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis.Cancer Res 2004;64:622-630[PMID:14744777 DOI:10 .1158/0008-5472.CAN-03-2636]
77 Chaturvedi P,Singh AP,Moniaux N,Senapati S,Chakraborty S,Meza JL,Batra SK.MUC4 mucin potentiates pancreatic tumor cell proliferation,survival,and invasive properties and interferes with its interaction to extracellular matrix proteins.Mol Cancer Res 2007;5:309-320[PMID:17406026 DOI:10.1158/1541-7786.MCR-06-0353]
78 Thériault C,Pinard M,Comamala M,Migneault M,Beaudin J,Matte I,Boivin M,PichéA,Rancourt C.MUC16(CA125)regulates epithelial ovarian cancer cell growth,tumorigenesis and metastasis.Gynecol Oncol 2011;121:434-443[PMID:21421261DOI:10.1016/j.ygyno.2011.02.020]
79 Reinartz S,Failer S,Schuell T,Wagner U.CA125(MUC16)gene silencing suppresses growth properties of ovarian and breast cancer cells.Eur J Cancer 2012;48:1558-1569[PMID:21852110 DOI:10 .1016/j.ejca.2011.07.004]
80 Shukla SK,Gunda V,Abrego J,Haridas D,Mishra A,Souchek J,Chaika NV,Yu F,Sasson AR,Lazenby AJ,Batra SK,Singh PK.MUC16-mediated activation of m TOR and c-Myc reprograms pancreatic cancer metabolism.Oncotarget 2015;6:19118-19131[PMID:26046375 DOI:10.18632/oncotarget.4078]
81 Giannakouros P,Comamala M,Matte I,Rancourt C,PichéA.MUC16 mucin(CA125)regulates the formation of multicellular aggregates by alteringβ-catenin signaling.Am J Cancer Res 2015;5:219-230[PMID:25628932]
82 Giannakouros P,Matte I,Rancourt C,PichéA.Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin(CA125)is driven by its cytoplasmic tail.Int J Oncol 2015;46:91-98[PMID:25338620 DOI:10.3892/ijo.2014.2707]
83 Grille SJ,Bellacosa A,Upson J,Klein-Szanto AJ,van Roy F,LeeKwon W,Donowitz M,Tsichlis PN,Larue L.The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines.Cancer Res 2003;63:2172-2178[PMID:12727836]
84 Balmanno K,Cook SJ.Tumour cell survival signalling by the ERK1/2 pathway.Cell Death Differ 2009;16:368-377[PMID:18846109 DOI:10.1038/cdd.2008.148]
85 Rao TD,Tian H,Ma X,Yan X,Thapi S,Schultz N,Rosales N,Monette S,Wang A,Hyman DM,Levine DA,Solit D,Spriggs DR.Expression of the Carboxy-Terminal Portion of MUC16/CA125Induces Transformation and Tumor Invasion.PLo S One 2015;10:e0126633[PMID:25965947 DOI:10.1371/journal.pone.0126633]
86 Al-Alem L,Curry TE.Ovarian cancer:involvement of the matrix metalloproteinases.Reproduction 2015;150:R55-R64[PMID:25918438 DOI:10.1530/REP-14-0546]
87 Kulbe H,Chakravarty P,Leinster DA,Charles KA,Kwong J,Thompson RG,Coward JI,Schioppa T,Robinson SC,Gallagher WM,Galletta L,Salako MA,Smyth JF,Hagemann T,Brennan DJ,Bowtell DD,Balkwill FR.A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.Cancer Res 2012;72:66-75[PMID:22065722 DOI:10.1158/0008-5472.CAN-11-2178]
88 Carraway KL,Funes M,Workman HC,Sweeney C.Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways.Curr Top Dev Biol 2007;78:1-22[PMID:17338913 DOI:10.1016/S0070-2153(06)78001-2]
89 Ren J,Agata N,Chen D,Li Y,Yu WH,Huang L,Raina D,Chen W,Kharbanda S,Kufe D.Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.Cancer Cell 2004;5:163-175[PMID:14998492]
90 Singh PK,Hollingsworth MA.Cell surface-associated mucins in signal transduction.Trends Cell Biol 2006;16:467-476[PMID:16904320 DOI:10.1016/j.tcb.2006.07.006]
91 Li Y,Liu D,Chen D,Kharbanda S,Kufe D.Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.Oncogene 2003;22:6107-6110[PMID:12955090 DOI:10.1038/sj.onc.1206732]
92 Bafna S,Singh AP,Moniaux N,Eudy JD,Meza JL,Batra SK.MUC4,a multifunctional transmembrane glycoprotein,induces oncogenic transformation of NIH3T3 mouse fibroblast cells.Cancer Res 2008;68:9231-9238[PMID:19010895 DOI:10 .1158/0008-5472.CAN-08-3135]
93 Auersperg N,Wong AS,Choi KC,Kang SK,Leung PC.Ovarian surface epithelium:biology,endocrinology,and pathology.Endocr Rev 2001;22:255-288[PMID:11294827 DOI:10.1210/er.22.2.255]
94 Boivin M,Lane D,PichéA,Rancourt C.CA125(MUC16)tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.Gynecol Oncol 2009;115:407-413[PMID:19747716 DOI:10.1016/j.ygyno.2009.08.007]
95 Yin L,Huang L,Kufe D.MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress.J Biol Chem 2004;279:45721-45727[PMID:15322085 DOI:10.1074/jbc.M408027200]
96 Nemoto S,Finkel T.Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway.Science 2002;295:2450-2452[PMID:11884717 DOI:10.1126/science.1069004]
97 Tran H,Brunet A,Grenier JM,Datta SR,Fornace AJ,Di Stefano PS,Chiang LW,Greenberg ME.DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45protein.Science 2002;296:530-534[PMID:11964479 DOI:10 .1126/science.1068712]
98 Khaider NG,Lane D,Matte I,Rancourt C,PichéA.Targeted ovarian cancer treatment:the TRAILs of resistance.Am J Cancer Res 2012;2:75-92[PMID:22206047]
99 Ashkenazi A,Dixit VM.Death receptors:signaling and modulation.Science 1998;281:1305-1308[PMID:9721089 DOI:10.1126/science.281.5381.1305]
100 Ashkenazi A,Holland P,Eckhardt SG.Ligand-based targeting of apoptosis in cancer:the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand(rh Apo2L/TRAIL).J Clin Oncol 2008;26:3621-3630[PMID:18640940 DOI:10.1200/JCO.2007.15.7198]
101 Walczak H,Miller RE,Ariail K,Gliniak B,Griffith TS,Kubin M,Chin W,Jones J,Woodward A,Le T,Smith C,Smolak P,Goodwin RG,Rauch CT,Schuh JC,Lynch DH.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.Nat Med1999;5:157-163[PMID:9930862 DOI:10.1038/5517]
102 Lane D,Cartier A,L’Espérance S,C?téM,Rancourt C,PichéA.Differential induction of apoptosis by tumor necrosis factorrelated apoptosis-inducing ligand in human ovarian carcinoma cells.Gynecol Oncol 2004;93:594-604[PMID:15196850 DOI:10 .1016/j.ygyno.2004.03.029]
103 Kischkel FC,Lawrence DA,Chuntharapai A,Schow P,Kim KJ,Ashkenazi A.Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.Immunity 2000;12:611-620[PMID:10894161 DOI:10.1016/S1074-7613(00)80212-5]
104 Kischkel FC,Hellbardt S,Behrmann I,Germer M,Pawlita M,Krammer PH,Peter ME.Cytotoxicity-dependent APO-1(Fas/CD95)-associated proteins form a death-inducing signaling complex(DISC)with the receptor.EMBO J 1995;14:5579-5588[PMID:8521815]
105 Krueger A,Baumann S,Krammer PH,Kirchhoff S.FLICEinhibitory proteins:regulators of death receptor-mediated apoptosis.Mol Cell Biol 2001;21:8247-8254[PMID:11713262 DOI:10 .1128/MCB.21.24.8247-8254.2001]
106 Matte I,Lane D,Boivin M,Rancourt C,PichéA.MUC16 mucin(CA125)attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.BMC Cancer 2014;14:234[PMID:24690311 DOI:10.1186/1471-2407-14-234]
107 Agata N,Ahmad R,Kawano T,Raina D,Kharbanda S,Kufe D.MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8.Cancer Res 2008;68:6136-6144[PMID:18676836 DOI:10.1158/0008-5472.CAN-08-0464]